论文部分内容阅读
美国食品和药物管理局(FDA)于2011年6月9日发布公告,称5-α还原酶抑制剂(5-ARI)可能会增加罹患高分级前列腺癌(high-grade prostate cancer)的风险。5-ARI类药物包括非那雄胺(finasteride)和度他雄胺(dutasteride),常用于治疗和控制良性前列腺增生(BPH)、男性雄激素性脱发,降低尿潴留或前列腺增生患者进行手术的风险。
The U.S. Food and Drug Administration (FDA) issued a public notice on June 9, 2011, stating that 5-AR reductase (5-ARI) may increase the risk of developing high-grade prostate cancer. 5-ARI drugs, including finasteride and dutasteride, are commonly used in the treatment and control of benign prostatic hyperplasia (BPH), androgenetic alopecia in men, urinary retention, or benign prostatic hyperplasia risk.